Academic Profile

please refer to for a biosketch
pdroge_1_2.JPG picture
Assoc Prof Peter Droge
Associate Professor, School of Biological Sciences

please refer to for a detailed description
  • A Versatile Singapore-based Proprietary Transgenesis Platform for the Biopharmaceutical and Soft Commodity Sector

  • Contribution towards NRF-CRP21-2018-0002

  • Engineering human iPSC-derived CAR-NK cells for improved cancer immunotherapy
  • Makhija H, Roy S, Hoon S, Ghadessy FJ, Wong D, Jaiswal R, Campana D, Dröge P. (2018). A novel λ integrase-mediated seamless vector transgenesis platform for therapeutic protein expression.. Nucleic Acids Research, 46(16), e99.

  • EYD Chua*, GE Davey*, CF Chin, P Droge, WH Ang, CA Davey. (2015). Stereochemical Control of Nucleosome Targeting by Platinum-Intercalator Antitumour Agents. Nucleic Acids Research, in press.

  • Z Adhireksan*, GE Davey*, P Campomanes, M Groessl, CM Clavel, H Yu, A Nazarov, CHF Yeo, WH Ang, P Droge, U Roethlisberger, PJ Dyson, CA Davey. (2014). Ligand Substitutions between Ruthenium-Cymene Compounds Can Control Protein versus DNA Targeting and Anticancer Activity. Nature Communications, .

  • Haojie Yu, Hong Hwa Lim, Natalia O. Tjokro, Padmapriya Sathiyanathan, Suchitra Natarajan, Tian Wei Chew, Thomas Klonisch, Steven D. Goodman, Uttam Surana & Peter Dröge. (2014). Chaperoning HMGA2 protein protects stalled replication forks in stem and cancer cells. Cell Reports, .

  • Kurt Pfannkuche, Heike Summer, Ou Li, Jürgen Hescheler and Peter Dröge. (2009). The high mobility group protein HMGA2: a co-regulator of global chromatin structure and pluripotency in stem cells?. Stem Cell Reviews, .